Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01016028 | Chemotherapy-Induced Peripheral Neuropathy Survey | — | withdrawn | Nov 18, 2009 | M.D. Anderson Cancer Center | Study assessment tool development delayed. | Other (stated, no rule matched) |
| NCT00578461 | T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE(REGKINE) | N/A | terminated | Dec 21, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT00578539 | T-Reg Cell Kinetics, Stem Cell Transplant, REGALE(REGALE) | N/A | terminated | Dec 21, 2007 | Baylor College of Medicine | not stated | Not stated |
| NCT00142168 | CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Sep 2, 2005 | Dana-Farber Cancer Institute | Toxicity | Safety / toxicity |
| NCT01578343 | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma(ZOLINZA) | Phase 2 | terminated | Apr 16, 2012 | Samsung Medical Center | we collected data of a total of 19 patients for an interim analysis. but there are less than 7… | Efficacy / futility |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of… | Phase 1 / Phase 2 | terminated | Dec 2, 2009 | Cephalon | not stated | Not stated |
| NCT02140840 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the… | Phase 2 | withdrawn | May 16, 2014 | University of Arkansas | PI left institution | Investigator |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity… | Phase 2 | terminated | Feb 14, 2008 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | Phase 2 | terminated | Jan 25, 2012 | M.D. Anderson Cancer Center | Objectives not met. | Other (stated, no rule matched) |
| NCT00836173 | Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate,… | Phase 2 | withdrawn | Feb 4, 2009 | Loyola University | Gallium is no longer available for the conduct of this study. | Other (stated, no rule matched) |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL(ASPIRE) | Phase 3 | withdrawn | Feb 4, 2014 | Asan Medical Center | No consensus among trial centers regarding protocol | Other (stated, no rule matched) |
| NCT00337259 | Gemcitabine for Marginal Zone Lymphoma | Phase 2 | terminated | Jun 15, 2006 | Asan Medical Center | poor accrual and response less than expected on interim analysis | Efficacy / futility |
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma…(VEIL) | Phase 2 | terminated | Dec 28, 2011 | Peter MacCallum Cancer Centre, Australia | Poor recruitment rate | Enrollment / accrual |
| NCT01329289 | SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2011 | University of Pittsburgh | Clinical trial being transferred to Columbia University with the Investigator. | Investigator |
| NCT00310128 | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in… | Phase 2 | withdrawn | Apr 3, 2006 | AIDS Malignancy Consortium | Drug supply unavailable | Drug supply |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT00575965 | Simvastatin in Waldenstrom's Macroglobulinemia | Phase 2 | terminated | Dec 18, 2007 | Dana-Farber Cancer Institute | Slow accrual led to early study termination. | Enrollment / accrual |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT00538187 | Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent… | Phase 1 | terminated | Oct 2, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT00384150 | Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) | Phase 3 | terminated | Oct 5, 2006 | Biogen | Enrollment challenges due to changes in standards of care resulted in premature termination. No… | Safety / toxicity |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell… | Phase 1 | terminated | Jan 11, 2010 | Case Comprehensive Cancer Center | Extreme toxicity in Phase I, study did not proceed to Phase II | Safety / toxicity |
| NCT01050946 | Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related…(Haplo/Cord) | Phase 2 | terminated | Jan 18, 2010 | Medical College of Wisconsin | Only one patient was enrolled. Due to low accrual study was terminated | Enrollment / accrual |
| NCT02000986 | Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger… | N/A | withdrawn | Dec 4, 2013 | Virginia Commonwealth University | Slow accrual | Enrollment / accrual |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT00578045 | UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies | Phase 1 | withdrawn | Dec 20, 2007 | University of Arkansas | no accrual | Enrollment / accrual |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT01263418 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell… | Phase 2 | withdrawn | Dec 20, 2010 | UNC Lineberger Comprehensive Cancer Center | No patients enrolled and funding has been withdrawn. | Enrollment / accrual |
| NCT00363636 | A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's… | Phase 3 | terminated | Aug 15, 2006 | Biogen | Enrollment challenges due to changes in standards of care resulted in premature termination. No… | Safety / toxicity |
| NCT01180569 | Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma | Phase 1 / Phase 2 | withdrawn | Aug 12, 2010 | Memorial Sloan Kettering Cancer Center | not stated | Not stated |
| NCT01119794 | Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That… | Phase 2 | terminated | May 10, 2010 | Brown University | lack of accrual | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | Phase 1 / Phase 2 | terminated | Aug 6, 2009 | German Low Grade Lymphoma Study Group | Predefined termination criterion of \> 10 patients without CR or PR was matched. | Other (stated, no rule matched) |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Mar 30, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | Phase 2 | terminated | Nov 8, 2005 | New Mexico Cancer Research Alliance | Low rate of accrual | Enrollment / accrual |
| NCT01889420 | Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With… | Phase 1 | terminated | Jun 28, 2013 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous…(PXD101-CLN-6) | Phase 2 | terminated | Jan 11, 2006 | Valerio Therapeutics | Enrollment stopped prior to reaching expected number of patients, study had accumulated sufficient… | Enrollment / accrual |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular… | Phase 2 | terminated | Aug 15, 2006 | National Cancer Institute (NCI) | Study terminated due to low accrual and the investigator left the NIH. | Investigator |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | terminated | Dec 22, 2011 | Duke University | Low accrual due to the approval of new drugs for use in Mantle cell lymphoma. | Enrollment / accrual |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed,… | Phase 2 | terminated | Feb 5, 2007 | Valerio Therapeutics | Terminated due to dose limiting toxicity | Safety / toxicity |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed… | Phase 2 | terminated | Oct 15, 2007 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00522392 | Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With… | Phase 3 | terminated | Aug 29, 2007 | National Cancer Institute (NCI) | Slow accrual | Enrollment / accrual |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | Phase 2 | withdrawn | May 1, 2013 | Stefan Schieke MD | not stated | Not stated |
| NCT01846429 | Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain | Phase 1 | terminated | May 3, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable. Study did not progress to Phase 2. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 3, 2016source: clinicaltrials